Please assess the completion status of the following clinical trial:

Trial Title: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases~* Decision to initiate treatment with Radium-223 was made as per investigator's routine treatment practice~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Type: None): Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).